Latest news with #ElizabethEvans
Yahoo
27-05-2025
- Business
- Yahoo
QXO Announces Five Female Roofing Professional of the Year Finalists
Public voting is open now through June 10 at GREENWICH, Conn., May 27, 2025--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO) today announced that five trailblazing women have been named finalists in the 2025 North American Female Roofing Professional of the Year program, an annual campaign celebrating the outstanding contributions, leadership and professionalism of women in the roofing industry. Now in its fifth year, the program shines a spotlight on female roofing professionals who are making a difference through innovation, mentorship, safety and a commitment to excellence in their field. These finalists represent the future of roofing across North America. The five 2025 finalists are: Elizabeth Evans, Founder and CEO, E2 Roofing, Jacksonville, FL Stacey Lytton, COO, Horch Roofing, Warren, ME Rachel Narveson, Founder and CEO, Proficient Construction, Lake Elmo, MN Sarah Sutton-Shouse, Service Manager, Raincoat Roofing, Broadview, IL Skye Williams, Founder and CEO, Samurai Roofing Services, Houston, TX QXO Chief Human Resources Officer Josephine Berisha said, "These five extraordinary finalists possess the talent, grit and leadership qualities that raise the bar for our entire industry. At QXO, we're proud to celebrate women who master their craft and inspire the next generation to reach even higher." This year's finalists were selected from over 1,000 nominations across the US and Canada. The finalist selection committee was made up of female leaders across the industry including the Chair of National Women in Roofing, the publisher of Roofing Contractor, the president of female roofers and select leaders from QXO. QXO invites the public to vote for their choice for the grand prize winner May 27 through June 10, 2025 by visiting the Female Roofing Professional of the Year program website at The five finalists will receive funding that can be used to support their professional development with the grand prize winner receiving $10,000. The grand prize winner will be announced on June 18, 2025, and celebrated across industry platforms, highlighting the vital role women play in shaping the future of roofing. About QXO QXO is the largest publicly traded distributor of roofing, waterproofing and complementary building products in the United States. The company plans to become the tech-enabled leader in the $800 billion building products distribution industry and generate outsized value for shareholders. QXO is targeting $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth. Visit for more information. View source version on Contacts Media: Joe 203-609-9650 Christina AlvarezMulberry Marketing Communicationscalvarez@ 708-908-0898 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
27-05-2025
- Business
- Business Wire
QXO Announces Five Female Roofing Professional of the Year Finalists
GREENWICH, Conn.--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO) today announced that five trailblazing women have been named finalists in the 2025 North American Female Roofing Professional of the Year program, an annual campaign celebrating the outstanding contributions, leadership and professionalism of women in the roofing industry. 'These five extraordinary finalists possess the talent, grit and leadership qualities that raise the bar for our entire industry. At QXO, we're proud to celebrate women who master their craft and inspire the next generation to reach even higher.' Share Now in its fifth year, the program shines a spotlight on female roofing professionals who are making a difference through innovation, mentorship, safety and a commitment to excellence in their field. These finalists represent the future of roofing across North America. The five 2025 finalists are: Elizabeth Evans, Founder and CEO, E2 Roofing, Jacksonville, FL Stacey Lytton, COO, Horch Roofing, Warren, ME Rachel Narveson, Founder and CEO, Proficient Construction, Lake Elmo, MN Sarah Sutton-Shouse, Service Manager, Raincoat Roofing, Broadview, IL Skye Williams, Founder and CEO, Samurai Roofing Services, Houston, TX QXO Chief Human Resources Officer Josephine Berisha said, 'These five extraordinary finalists possess the talent, grit and leadership qualities that raise the bar for our entire industry. At QXO, we're proud to celebrate women who master their craft and inspire the next generation to reach even higher.' This year's finalists were selected from over 1,000 nominations across the US and Canada. The finalist selection committee was made up of female leaders across the industry including the Chair of National Women in Roofing, the publisher of Roofing Contractor, the president of female roofers and select leaders from QXO. QXO invites the public to vote for their choice for the grand prize winner May 27 through June 10, 2025 by visiting the Female Roofing Professional of the Year program website at The five finalists will receive funding that can be used to support their professional development with the grand prize winner receiving $10,000. The grand prize winner will be announced on June 18, 2025, and celebrated across industry platforms, highlighting the vital role women play in shaping the future of roofing. About QXO QXO is the largest publicly traded distributor of roofing, waterproofing and complementary building products in the United States. The company plans to become the tech-enabled leader in the $800 billion building products distribution industry and generate outsized value for shareholders. QXO is targeting $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth. Visit for more information.
Associated Press
21-04-2025
- Business
- Associated Press
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in 'cold' tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies, corresponding with improved survival benefit in patients with melanoma and head and neck cancer at the 2025 Annual Meeting of American Association for Cancer Research (AACR) in Chicago on April 29, 2025. Elizabeth Evans, PhD, Senior VP Discovery and Translational Medicine, will present results of these studies in two presentations . Previously reported data from these two clinical studies suggest a crucial role of pepinemab to facilitate immune cell interactions within highly organized and robust centers of immunity, called tertiary lymphoid structures, or TLS. By blocking the SEMA4D inhibitory signal to Dendritic Cells (DC), pepinemab allows productive, coordinated interactions between SEMA4D+ T cells, key effector cells capable of eradicating tumors, and DC, regulatory cells that promote immune cell interactions within TLS so as to amplify mature T cell responses. New data will characterize clinical outcomes, biomarkers, and mechanisms of these interactions in patients treated with pepinemab in combination with immune checkpoint therapy. Boosting TLS within tumors is an area of growing excitement because the presence of TLS has been shown to correlate with clinical benefit and positive response to immune checkpoint therapy. A limitation in the field has been identification of safe and effective therapies that can induce formation and harness the potential of TLS to enable durable benefit to patients. Pepinemab may represent a solution to this problem, as our data demonstrate the potential of pepinemab to turn immunologically cold tumors, such as HPV-negative and PD-L1-low head and neck cancer, into hot immune centers by inducing robust and mature TLS. Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of various cancers, showing improved immune and clinical benefit in the preoperative setting compared to standard post surgery adjuvant treatments. Despite these advances, many patients who initially benefit from antibodies that block inhibitory checkpoint molecules (e.g. PD-1, CTLA 4) will progress. More effective combination therapies are needed. Neoadjuvant treatment with pepinemab enhanced TLS maturity and correlated with longer recurrence-free survival when combined with immune checkpoint inhibitors in patients with metastatic melanoma. Evaluation of pepinemab in the neoadjuvant setting for patients with head and neck cancer is ongoing and will be reported at upcoming scientific meeting this Spring. About Pepinemab Pepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can otherwise bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton in cells and lead to loss of homeostatic functions of dendritic cells in immune tissue and of astrocytes and other glial cells in the brain. Pepinemab appears to be well-tolerated with a favorable safety profile in multiple clinical trials in different cancer and neurological indications. About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents infiltration and activation of immune cells in tumors and triggers damaging inflammation in neurodegenerative diseases. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. We believe pepinemab has also given promising results as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer's Disease, and the Company has previously published promising Phase 2 data suggesting a slowing of cognitive decline in Huntington's disease. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. BAVENCIO®/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. ('Vaccinex,' 'we,' 'us,' or 'our'), they are forward-looking statements reflecting management's current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of the SIGNAL-AD and KEYNOTE-B84 clinical trials; the use and potential benefits of pepinemab in R/M HNSCC, lung cancer, metastatic pancreatic adenocarcinoma (PDAC) and other indications; the potential for benefits as compared to single agent KEYTRUDA® or BAVENCIO®; expectations with respect to the collaboration of Merck,; and other statements identified by words such as 'anticipate,' 'believe,' 'plans,' 'schedule,' 'being,' 'will,' 'appears,' 'expect,' 'ongoing,' 'potential,' 'promising,' 'suggest', and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled 'Risk Factors' in our previous reports filed with the Securities and Exchange Commission and the other risks and uncertainties described in the Company's annual year-end Form 10-K filed with the SEC. Investor Contact Elizabeth Evans, PhD Senior Vice President, Vaccinex, Inc. (585) 271-2700 [email protected]
Yahoo
04-04-2025
- Business
- Yahoo
Why a Roth IRA might be the MVP of retirement savings
The Roth IRA is a powerful retirement account that offers savers unique tax breaks, flexible withdrawal options, optimal wealth-transfer perks and more. It's easy to set up a Roth account on your own or with a financial advisor and Roth IRAs are available to all working Americans and their spouses. Here are five top benefits of a Roth IRA and why you should seriously consider getting a Roth IRA. Let's start with the biggest advantages of a Roth IRA, the ones that will keep the government out of your pocket permanently — tax-free growth and withdrawals. 'Roth IRAs are one of the best vehicles to save for retirement, given the tremendous benefit of tax-free growth,' says Elizabeth Evans, CFP and managing partner of Evans May Wealth in the Indianapolis area. With a Roth IRA, you contribute after-tax money to the account, so you don't get to avoid tax on your contributions, as you might with a traditional IRA. In exchange, your money grows tax-free and you'll be able to withdraw it tax-free at retirement, defined as age 59½ or older. The Roth IRA is a powerful way to grow your nest egg. But even those who have a traditional IRA may convert it to a Roth IRA and reap the benefits by doing a backdoor Roth conversion. Converting a traditional IRA to a Roth IRA will likely trigger a tax bill. A financial advisor who is well-versed in tax matters can identify ways to minimize the hit. Unlike some retirement accounts that can ding you with penalties if you need to withdraw some money before retirement, the Roth IRA allows you to withdraw contributions at any time tax- and penalty-free five years after opening the account. The key word here is contributions, that is, only the money you've added. If you take out earnings before you're able to make a qualified withdrawal, you'll owe taxes on them. If you run into an emergency and need to access cash, a Roth IRA offers you a lot of flexibility. While experts advise not tapping your account, sometimes you don't have a choice and it can be a relief to know that you can do so without the extra burden of taxes and penalties. The Roth IRA is a great wealth transfer vehicle because it allows you to pass any money in the account tax-free to your heirs. Depending on the circumstances, heirs could still grow the account tax-free for years, maybe decades, while other heirs may need to distribute all the assets in the account within 10 years of the original owner's death. But because that money is in a Roth IRA, any distributions will ultimately be tax-free to recipients. The rules around inherited IRAs are quite tricky, however, so it's important to understand them before diving in. But the Roth IRA puts a ton of tax-free options at the disposal of your heirs. Need an advisor? If you're looking for expert guidance when it comes to planning for retirement or managing your investments, Bankrate's AdvisorMatch can connect you to a CFP® professional to help you achieve your financial goals. As long as you have earned income from working (not merely investments), you can contribute to a Roth IRA at any age. Even children can have custodial Roth accounts. Your contribution can be no more than $7,000 (in 2025) or your earned income, whichever is less. However, those over age 50 can contribute an extra $1,000 per year. In addition, non-working spouses can contribute to a Roth IRA if they have a spouse who earns income. Here are the details on the spousal IRA. Traditional IRAs impose required minimum distributions (RMDs) as do traditional 401(k)s. You don't have to worry about RMDs in a Roth IRA or its Roth 401(k) cousin. As the name suggests, RMDs force you to take a minimum distribution from your account annually the year after you turn 73. With an RMD, you'll be forced to withdraw money whether you need it or not. And that means taxes and a halt to the tax-advantaged compounding inside the account. But the Roth IRA lets you avoid required minimum distributions entirely, allowing your money to continue compounding as long as you like, even passing that money untouched to your heirs tax-free. While there are many benefits of Roth IRAs, there are a few drawbacks to be aware of. The most obvious disadvantage of contributing to a Roth IRA is that your contributions are made with after-tax dollars, unlike traditional IRAs or 401(k) plans. This means you won't get a tax benefit in the year you make the contribution, but it will ultimately benefit you down the road when you won't owe taxes on withdrawals during retirement. Another disadvantage of Roth IRAs is that not everyone can contribute to them. Once you reach a certain level of income, the amount you can contribute declines and is eventually eliminated at a certain level of income. However, as mentioned above, there are ways around this cutoff by using a backdoor Roth IRA. Wondering if a Roth IRA is right for you? How much of your retirement savings should be invested in a Roth account? Ask a financial advisor! The Roth IRA is one of the best retirement accounts around, offering tons of flexibility as well as the ability to grow your money tax-free, potentially for decades. — Bankrate's Dayana Yochim contributed to an update. Editorial Disclaimer: All investors are advised to conduct their own independent research into investment strategies before making an investment decision. In addition, investors are advised that past investment product performance is no guarantee of future price appreciation.
